Lexicon Pharmaceuticals (LXRX) Cash from Operations Growth (1y) (2011 - 2026)
Lexicon Pharmaceuticals (LXRX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Lexicon Pharmaceuticals | 888.49 Mn | 717.83 Mn | 20.99 Mn | 66.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.35% |
| Dec 31, 2025 | 19.81% |
| Sep 30, 2025 | 55.55% |
| Jun 30, 2025 | 135.01% |
| Mar 31, 2025 | 20.59% |
| Dec 31, 2024 | 57.48% |
| Sep 30, 2024 | -28.83% |
| Jun 30, 2024 | -27.34% |
| Mar 31, 2024 | -74.39% |
| Dec 31, 2023 | -134.35% |
| Sep 30, 2023 | -114.10% |
| Jun 30, 2023 | -56.08% |
| Mar 31, 2023 | -34.98% |
| Dec 31, 2022 | 5.52% |
| Sep 30, 2022 | -13.35% |
| Jun 30, 2022 | -11.62% |
| Mar 31, 2022 | 6.91% |
| Dec 31, 2021 | 33.33% |
| Sep 30, 2021 | 57.53% |
| Jun 30, 2021 | 52.74% |